[go: up one dir, main page]

MX2017000087A - Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer. - Google Patents

Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer.

Info

Publication number
MX2017000087A
MX2017000087A MX2017000087A MX2017000087A MX2017000087A MX 2017000087 A MX2017000087 A MX 2017000087A MX 2017000087 A MX2017000087 A MX 2017000087A MX 2017000087 A MX2017000087 A MX 2017000087A MX 2017000087 A MX2017000087 A MX 2017000087A
Authority
MX
Mexico
Prior art keywords
compounds
cancer
novel
rexinoid
methods
Prior art date
Application number
MX2017000087A
Other languages
English (en)
Inventor
J Brouillette Wayne
D Muccio Donald
Reddy Atigadda Venkatram
J Grubbs Clinton
KIM Jeonga
Original Assignee
Uab Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Res Found filed Critical Uab Res Found
Publication of MX2017000087A publication Critical patent/MX2017000087A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/38—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
    • C07C57/40—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/62—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33—Polycyclic acids
    • C07C63/331—Polycyclic acids with all carboxyl groups bound to non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan en la presente compuestos rexinoides novedosos. También se proporcionan en la presente métodos para usar los compuestos para tratar trastornos, tales como trastornos metabólicos, diabetes, resistencia a la insulina, intolerancia a la glucosa, obesidad, esteatosis, inflamación y/o cáncer.
MX2017000087A 2014-06-30 2015-06-30 Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer. MX2017000087A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019170P 2014-06-30 2014-06-30
PCT/US2015/038596 WO2016004066A1 (en) 2014-06-30 2015-06-30 Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer

Publications (1)

Publication Number Publication Date
MX2017000087A true MX2017000087A (es) 2017-08-16

Family

ID=55019924

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000087A MX2017000087A (es) 2014-06-30 2015-06-30 Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer.

Country Status (5)

Country Link
US (2) US10800726B2 (es)
EP (1) EP3160508B1 (es)
CA (1) CA2953962A1 (es)
MX (1) MX2017000087A (es)
WO (1) WO2016004066A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030161A1 (en) * 2023-08-02 2025-02-06 The Uab Research Foundation Rexinoids for treatment of ocular diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094783A (en) 1990-06-29 1992-03-10 Uab Research Foundation Retinoid compounds
KR20020067050A (ko) * 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
CA2495903A1 (en) * 2002-08-23 2004-03-04 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
WO2005063222A1 (ja) 2003-12-26 2005-07-14 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
AU2005290080A1 (en) 2004-08-24 2006-04-06 The Uab Research Foundation Methods for making retinoids and uses thereof
WO2006057922A2 (en) * 2004-11-23 2006-06-01 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2643972C (en) 2006-04-19 2012-01-03 Peter Demin Hepoxilin analog enantiomers
CN102295642B (zh) 2010-06-25 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途

Also Published As

Publication number Publication date
CA2953962A1 (en) 2016-01-07
US20210101861A1 (en) 2021-04-08
EP3160508B1 (en) 2020-08-05
EP3160508A1 (en) 2017-05-03
EP3160508A4 (en) 2018-04-18
US10800726B2 (en) 2020-10-13
US20180201565A1 (en) 2018-07-19
WO2016004066A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
PH12017500153A1 (en) Compositions and methods of use for treating metabolic disorders
PH12017500680A1 (en) Compositions and methods of use for treating metabolic disorders
GB2541571A (en) Pharmaceutical compositions
PH12016501978B1 (en) Treatment of nafld and nash
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12017500809A1 (en) Improved il-6 antibodies
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
EP3137082A4 (en) Methods to treat, prevent, and improve skin conditions
TW201613587A (en) Medical treatments based on anamorelin
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX2017000087A (es) Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer.
MX2018011512A (es) Uso de insulina para promover el vaciamiento gástrico.
NZ730759A (en) 1,2-benzothiazole compounds for the treatment of kidney disorders
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
HK1259634A1 (en) Electroporation for obesity or diabetes treatment
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
UA107743C2 (ru) Способ лечения аденокарциномы